NASDAQ:FLXN Flexion Therapeutics (FLXN) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free FLXN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.12▼$9.1250-Day Range$9.12▼$9.4452-Week Range$4.30▼$13.66VolumeN/AAverage Volume1.18 million shsMarket Capitalization$458.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Flexion Therapeutics alerts: Email Address Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Flexion Therapeutics Stock (NASDAQ:FLXN)Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. FLXN Stock News HeadlinesApril 19, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 11, 2024 | tmcnet.comFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 6, 2024 | seekingalpha.comVIRI Virios Therapeutics, Inc.February 14, 2024 | morningstar.comSpyre Therapeutics Inc SYREFebruary 10, 2024 | benzinga.comPFIZER INC's Net WorthNovember 24, 2023 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsJuly 11, 2023 | benzinga.comFlexion wins MCADS contract to modernize CMS Claims Handling SystemApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.July 10, 2023 | finance.yahoo.comFlexion achieves Select Tier Status within the AWS Partner NetworkJune 10, 2023 | yahoo.com7 Exercises to Stretch Plantar Flexion MovementMay 16, 2023 | marketwatch.com2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 PagesMay 4, 2023 | finance.yahoo.comOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone ExperienceApril 28, 2023 | marketwatch.comProne Leg Flexion Trainers Market Global Outlook and Projection till 2029April 12, 2023 | marketwatch.comAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028April 6, 2023 | marketwatch.comProne Leg Flexion Trainers Market 2023 Huge Demand, Growth Opportunities and Expansion by 2031March 23, 2023 | marketwatch.comGlobal Flexion Tires Market: Future Extrapolations and Emerging Updates for 2023-2027February 24, 2023 | msn.comOppo’s new Flexion hinge has made flip phones more practical and crease minimalSeptember 21, 2022 | seekingalpha.comPCRX Pacira BioSciences, Inc.September 1, 2022 | thestreet.comCoherus BioSciences Inc. NewsAugust 17, 2022 | venturebeat.comFlexion targets TikTok influencers on behalf of game developersJuly 2, 2022 | thestreet.comBiotech Movers: Akebia Soars on Expanded Partnership With OtsukaJanuary 13, 2022 | thestreet.comWhy Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading TodayNovember 3, 2021 | finance.yahoo.comPacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss MarkNovember 1, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing InvestigationsOctober 30, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXNOctober 30, 2021 | prnewswire.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXNSee More Headlines Receive FLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FLXN CUSIPN/A CIK1419600 Webwww.flexiontherapeutics.com Phone(781) 305-7777Fax781-202-3399Employees257Year Founded2007Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,710,000.00 Net Margins-100.32% Pretax Margin-100.32% Return on EquityN/A Return on Assets-44.26% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.05 Sales & Book Value Annual Sales$85.55 million Price / Sales5.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-26.82Miscellaneous Outstanding Shares50,321,000Free Float45,727,000Market Cap$458.93 million OptionableOptionable Beta1.53 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMichael D. ClaymanPresident, Chief Executive Officer & DirectorFred DriscollChief Financial OfficerWilliam T. AndrewsChief Medical OfficerCarolyn Beaty ScimemiChief Compliance Officer & Head-Legal AffairsChristina WillwerthChief Strategy OfficerKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCAvid BioservicesNASDAQ:CDMOAnnexonNASDAQ:ANNXMersana TherapeuticsNASDAQ:MRSNLarimar TherapeuticsNASDAQ:LRMRView All Competitors FLXN Stock Analysis - Frequently Asked Questions How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings data on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to the consensus estimate of $24.61 million. What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO? 46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees. What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM). This page (NASDAQ:FLXN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
